SetPoint Medical has discovered novel a groundbreaking neuroimmune modulation platform designed specifically for individuals with relapsing-remitting multiple sclerosis (RRMS).
This innovative therapeutic approach targets pathways aimed at promoting remyelination, offering new hope to those affected by this chronic condition.
The investigational platform technology, also undergoing pivotal trials for rheumatoid arthritis (RA) treatment, addresses the urgent unmet medical need for therapies promoting the protection and restoration of damaged axons through remyelination. This marks a significant advancement for patients grappling with the debilitating effects of MS.
The device is surgically placed on the vagus nerve via a minor outpatient procedure involving a small incision on the left side of the neck. Programmed to deliver therapy automatically on a preset schedule, it stimulates the vagus nerve once daily, activating the inflammatory reflex for a systemic immune-restorative effect.
Currently assessing its investigational platform technology in a pivotal human clinical trial called the RESET-RA study, targets adults with moderate-to-severe RA. Utilising precise vagus nerve stimulation, the integrated neurostimulation device activates innate anti-inflammatory and immune-restorative pathways to combat inflammation-mediated autoimmune conditions.
With nearly one million individuals in the United States living with multiple sclerosis, a condition characterised by damage to the myelin sheath surrounding nerve fibres, this breakthrough offers a promising avenue for addressing the root cause of MS.
While current medications may slow disease progression and alleviate symptoms to some extent, there remains a critical gap in treatments directly targeting myelin sheath damage.
